DiscoverThe Nucleus
The Nucleus
Claim Ownership

The Nucleus

Author: Regeneron

Subscribed: 3Played: 14
Share

Description

Regeneron’s “The Nucleus” podcast explores how biology and technology converge to shape the future of human health. Hosted by Regeneron’s leaders and featuring guest experts, each episode highlights innovations — from AI to large-scale genomics — driving breakthroughs in scientific research, drug discovery and precision medicine. Visit Regeneron.com to learn more about Regeneron.
5 Episodes
Reverse
In this collaborative episode of The Nucleus, Dr. John Overton, Vice President and Chief Sequencing Officer at our Regeneron Genetics Center (RGC), joins STAT Brand Studio’s Jesse McQuarters to explore how integrating proteomics and multi-omics can deliver deeper insight into how diseases develop, and how science can better predict and prevent them. 
What if CRISPR could do more than cut DNA? In this episode of The Nucleus, a Regeneron podcast, Leah Sabin, PhD, Executive Director, Regeneron Genetic Medicines, sits down with Janice Chen, PhD, Co-founder and CTO of Mammoth Biosciences to dive into the scientific collaboration to potentially change the future of genetic medicine.
We’ll dive into the future of clinical trials, including your work with sponsors to understand the challenges and how toovercome them — from what’s changing, what still needs to change and how we can leverage technology to make them more efficient. 
What happens when large-scale, cutting-edge genetic research meets broad population representation? In this episode of The Nucleus, a Regeneron podcast, listen to Eric Jorgenson, PhD, Senior Director, Statistical Genetics, Regeneron Genetics Center (RGC) and Marylyn Ritchie, PhD, Vice Dean of AI and Computing at the Perelman School of Medicine, University of Pennsylvania, explore how these two forces are revolutionizing precision medicine.
In our debut episode of The Nucleus, a Regeneron podcast, our first host Jeffrey Reid, PhD, VP, Chief Data Officer, Regeneron Genetics Center (RGC) and Daphne Koller, PhD, Founder and CEO, insitro examine how AI and ML are already being applied to tackle some of the most pressing challenges in science to transform the industry for years to come.
Comments